Phase 4 N=11 Ketoconazole Foam 2% for the Treatment of Versicolor
Tinea Versicolor
Primary: The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor — 7; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor
Tinea Versicolor
Primary: Molecular Diagnostic qPCR Comparison of DBI-002 Drug Product and Malassezia (Fungal Cause of Tinea Versicolor) — 2; 4; 5; 1 Participants — p=0.2
Phase 3 N=831 Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis
Tinea Pedis
Primary: Primary Efficacy Endpoint: The Number of Patients in Each Treatment Group With a Therapeutic Cure of Tinea Pedis (Equivalence: Per-Protocol Population) — 89; 90…
Phase 3 N=290 Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis
Tinea Pedis
Primary: Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2) — 73; 10 participants
Phase 4 N=56 Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
Tinea Pedis · Tinea Cruris
Primary: Naftifine Hydrochloride Pharmacokinetics Variables, Single and Multiple Dose — 138262.2; 15890.1; 68634.2; 17213.9 h*pg/mL
Phase 2 N=20 Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
Acne Vulgaris
Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants
Phase 3 N=876 Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
Tinea Pedis
Primary: Proportion of Patients in Each Active Treatment Group Who Are Considered a Therapeutic Cure — 96; 81 Participants
Phase 3 N=561 Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis
Tinea Pedis
Primary: Proportion of Subjects in Each Treatment Group With Therapeutic Success — 70; 95; 3 participants
Phase 3 N=137 Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants
Dermatitis, Photoallergic
Primary: Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects — 325; 24; 343; 6 Test site
Phase 3 N=334 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris
Tinea Cruris · Jock Itch
Primary: Percentage of Subjects — 25.3; 2.8 percentage of subjects with complete cur — p=0.025
N/A N=50 Spread of Dermatophytes Among Families
Onychomycosis · Tinea Pedis
Primary: Dermatophyte Species Distribution — 50; 37; 5; 12 isolates
Phase 4 N=6 Can We Miss Pigmented Lesions in Psoriasis Patients?
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
N/A N=553 Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis
Tinea Pedis
Primary: Proportion of Subjects in Each Treatment Group With Therapeutic Success — 93; 88; 7 participants
Phase 2 N=10 HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Primary: Number of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) Score — 3; 1 Participants
Phase 3 N=32 Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
Dermatitis, Phototoxic
Primary: Phototoxic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score — 77; 10; 85; 2 Test site
Phase 3 N=225 Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)
Hypersensitivity
Primary: Irritation Response Evaluation According to Erythema Scoring Scale During Induction Phase - All Enrolled Subjects — 2182; 2 Test site
Phase 2 N=50 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis
Tinea Pedis
Primary: Percentage of Subjects With Therapeutic Cure at 42 Days for All-analysis Population — 2; 1; 3; 0 Participants
Phase 1 N=548 Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis
Tinea Pedis
Primary: Therapeutic Cure - Superiority Analysis — 76; 108; 24 Participants — p=0.0127
Phase 2 N=20 Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Acne Vulgaris
Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit
N/A N=25 PHNA, Efficacy of Tretinoin Cream on Post-phototherapy Hyperpigmentation
Vitiligo
Primary: The Degree of Hyperpigmentation at 12 Weeks — 56.8; 57.6; 51.0; 54.3 score on a scale — p=0.002
Phase 3 N=707 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis
Tinea Pedis · Athlete's Foot
Primary: Percentage of Subjects With Complete Cure at Week 6. — 17.7; 7.1; 16.1; 3.1 percentage of subjects with complete cur — p=0.010
Phase 2 N=12 A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
Tinea Pedis
Primary: Safety Evaluation Cohort 1 — 8; 0; 0; 0 Feet
Phase 3 N=855 Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Tinea Pedis
Primary: Complete Cure of Interdigital Tinea Pedis — 16.8; 1.7 percentage of subjects — p=<0.025
Phase 3 N=326 Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis
Scalp Seborrheic Dermatitis
Primary: Total Severity Score (TSS): Percent Change From Baseline at Week 4 — -71.4; -66.7; -66.7; -57.1 Percent change — p=<0.01
Phase 2 N=88 Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)
Psoriasis Vulgaris · Topical Administration
Primary: Investigator's Static Global Assessment Scale (ISGA) Scores — 1.46; 2.02; 2.57; 2.60 Score
Phase 3 N=860 Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Tinea Pedis
Primary: Complete Cure of Interdigital Tinea Pedis — 26.0; 3.3 percentage of subjects — p=<0.025
Phase 4 N=10 A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
Acne Vulgaris
Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008
Phase 4 N=25 Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color
Plaque Psoriasis · Psoriasis
Primary: Number of Patients Who Achieved Treatment Success — 4; 0 Participants
Phase 3 N=169 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Cutaneous T-Cell Lymphoma
Primary: Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion…